nach oben

Acta Diabetologica

Erschienen in:

01.06.2013 | Short Communication

Polycystic ovary syndrome is not associated with genetic variants that mark risk of type 2 diabetes

verfasst von: R. Saxena, C. K. Welt

Erschienen in: Acta Diabetologica | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Polycystic ovary syndrome (PCOS) is a disorder of irregular menses, hyperandrogenism and/or polycystic ovary morphology. A large proportion of women with PCOS also exhibit insulin resistance, β-cell dysfunction, impaired glucose tolerance and/or type 2 diabetes (T2D). We therefore hypothesized that genetic variants that predispose to risk of T2D also result in risk of PCOS. Variants robustly associated with T2D in candidate gene or genome-wide association studies (GWAS; n = 56 SNPs from 33 loci) were genotyped in women of European ancestry with PCOS (n = 525) and controls (n = 472), aged 18–45 years. Metabolic, reproductive and anthropomorphic data were examined as a function of the T2D variants. All genetic association analyses were adjusted for age, BMI and ancestry and were reported after correction for multiple testing. There was a nominal association between variants in KCNJ11 and risk of PCOS. However, a risk score of 33 independent T2D-associated variants from GWAS was not significantly associated with PCOS. T2D variants were associated with PCOS phenotype parameters including those in THADA and WFS1 with testosterone levels, ENPP/PC1 with triglyceride levels, FTO with glucose levels and KCNJ11 with FSH levels. Diabetes risk variants are not important risk variants for PCOS.

Nur mit Berechtigung zugänglich

The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47

Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165–1174PubMedCrossRef

Chang RJ, Nakamura RM, Judd HL, Kaplan SA (1983) Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 57:356–359PubMedCrossRef

Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS (1995) Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 96:520–527PubMedCrossRef

Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141–146PubMedCrossRef

Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169PubMedCrossRef

Welt CK, Arason G, Gudmundsson JA et al (2006) Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations. J Clin Endocrinol Metab 91:4361–4368PubMedCrossRef

Conn JJ, Jacobs HS, Conway GS (2000) The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 52:81–86CrossRef

Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN (2005) Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:66–71PubMedCrossRef

10.

Zeggini E, Weedon MN, Lindgren CM et al (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336–1341PubMedCrossRef

11.

Zeggini E, Scott LJ, Saxena R et al (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40:638–645PubMedCrossRef

12.

Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336PubMedCrossRef

13.

Scott LJ, Mohlke KL, Bonnycastle LL et al (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341–1345PubMedCrossRef

14.

McAteer JB, Prudente S, Bacci S et al (2008) The ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects. Diabetes 57:1125–1130PubMedCrossRef

15.

Voight BF, Scott LJ, Steinthorsdottir V et al (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42:579–589PubMedCrossRef

16.

Rung J, Cauchi S, Albrechtsen A et al (2009) Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet 41:1110–1115PubMedCrossRef

17.

Grant SF, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedCrossRef

18.

Sandhu MS, Weedon MN, Fawcett KA et al (2007) Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet 39:951–953PubMedCrossRef

19.

Ewens KG, Jones MR, Ankener W et al (2011) Type 2 diabetes susceptibility single-nucleotide polymorphisms are not associated with polycystic ovary syndrome. Fertil Steril 95:2538–2541PubMedCrossRef

20.

Barber TM, Bennett AJ, Groves CJ et al (2007) Disparate genetic influences on polycystic ovary syndrome (PCOS) and type 2 diabetes revealed by a lack of association between common variants within the TCF7L2 gene and PCOS. Diabetologia 50:2318–2322PubMedCrossRef

21.

Barber TM, Bennett AJ, Gloyn AL et al (2007) Relationship between E23K (an established type II diabetes-susceptibility variant within KCNJ11), polycystic ovary syndrome and androgen levels. Eur J Hum Genet 15:679–684PubMedCrossRef

22.

Barber TM, Bennett AJ, Groves CJ et al (2008) Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. Diabetologia 51:1153–1158PubMedCrossRef

23.

Li C, Shi Y, You L, Wang L, Chen ZJ (2011) Association of rs10830963 and rs10830962 SNPs in the melatonin receptor (MTNR1B) gene among Han Chinese women with polycystic ovary syndrome. Mol Hum Reprod 17:193–198PubMedCrossRef

24.

Wang L, Wang Y, Zhang X et al (2010) Common genetic variation in MTNR1B is associated with serum testosterone, glucose tolerance, and insulin secretion in polycystic ovary syndrome patients. Fertil Steril 94(2486):2489

25.

American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69

26.

Biyasheva A, Legro RS, Dunaif A, Urbanek M (2009) Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2. J Clin Endocrinol Metab 94:2617–2625PubMedCrossRef

27.

Chen ZJ, Zhao H, He L et al (2011) Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 43:55–59PubMedCrossRef

28.

Price AL, Butler J, Patterson N et al (2008) Discerning the ancestry of European Americans in genetic association studies. PLoS Genet 4:e236PubMedCrossRef

29.

Price AL, Patterson N, Yu F et al (2007) A genomewide admixture map for Latino populations. Am J Hum Genet 80:1024–1036PubMedCrossRef

30.

Smith MW, Patterson N, Lautenberger JA et al (2004) A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet 74:1001–1013PubMedCrossRef

31.

Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559–575PubMedCrossRef

32.

Cornelis MC, Qi L, Zhang C et al (2009) Joint effects of common genetic variants on the risk for type 2 diabetes in U.S. men and women of European ancestry. Ann Intern Med 150:541–550PubMedCrossRef

33.

Christopoulos P, Mastorakos G, Gazouli M et al (2008) Genetic variants in TCF7L2 and KCNJ11 genes in a Greek population with polycystic ovary syndrome. Gynecol Endocrinol 24:486–490PubMedCrossRef

34.

Maciel GA, Baracat EC, Benda JA et al (2004) Stockpiling of transitional and classic primary follicles in ovaries of women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:5321–5327PubMedCrossRef

35.

Webber LJ, Stubbs S, Stark J et al (2003) Formation and early development of follicles in the polycystic ovary. Lancet 362:1017–1021PubMedCrossRef

36.

Hamming KS, Soliman D, Matemisz LC et al (2009) Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes 58:2419–2424PubMedCrossRef

37.

Karschin C, Ecke C, Ashcroft FM, Karschin A (1997) Overlapping distribution of K(ATP) channel-forming Kir6.2 subunit and the sulfonylurea receptor SUR1 in rodent brain. FEBS Lett 401:59–64PubMedCrossRef

38.

Spanswick D, Smith MA, Mirshamsi S, Routh VH, Ashford ML (2000) Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats. Nat Neurosci 3:757–758PubMedCrossRef

39.

Costanzo BV, Trischitta V, Di PR et al (2001) The Q allele variant (GLN121) of membrane glycoprotein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (LYS121). Diabetes 50:831–836PubMedCrossRef

40.

Gonzalez-Sanchez JL, Martinez-Larrad MT, Fernandez-Perez C, Kubaszek A, Laakso M, Serrano-Rios M (2003) K121Q PC-1 gene polymorphism is not associated with insulin resistance in a Spanish population. Obes Res 11:603–605PubMedCrossRef

41.

Shi X, Wang L, Jin F et al (2011) The ENPP1 K121Q polymorphism is not associated with type 2 diabetes in northern Chinese. Acta Diabetol 48:303–310PubMedCrossRef

42.

Heinonen S, Korhonen S, Helisalmi S, Koivunen R, Tapanainen JS, Laakso M (2004) The 121Q allele of the plasma cell membrane glycoprotein 1 gene predisposes to polycystic ovary syndrome. Fertil Steril 82:743–745PubMedCrossRef

43.

Inoue H, Tanizawa Y, Wasson J et al (1998) A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 20:143–148PubMedCrossRef

44.

Ewens KG, Jones MR, Ankener W et al (2011) FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS ONE 20(6):e16390CrossRef

45.

Wehr E, Schweighofer N, Moller R, Giuliani A, Pieber TR, Obermayer-Pietsch B (2010) Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome. Metabolism 59:575–580PubMedCrossRef

46.

Freathy RM, Timpson NJ, Lawlor DA et al (2008) Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes 57:1419–1426PubMedCrossRef

Titel: Polycystic ovary syndrome is not associated with genetic variants that mark risk of type 2 diabetes
verfasst von: R. Saxena
C. K. Welt
Publikationsdatum: 01.06.2013
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 3/2013
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-012-0383-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Polycystic ovary syndrome is not associated with genetic variants that mark risk of type 2 diabetes

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Achieving glycemic control in patients with type 2 diabetes and renal impairment

PPARG2 Pro12Ala and ADAMTS9 rs4607103 as “insulin resistance loci” and “insulin secretion loci” in Italian individuals. The GENFIEV study and the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 4

The glucose dysmetabolism in the acute phase of non-diabetic ST-elevation myocardial infarction: from insulin resistance to hyperglycemia

Trialogue

Total bilirubin is inversely associated with metabolic syndrome but not a risk factor for metabolic syndrome in Japanese men and women

Influence of heart rate at rest for predicting the metabolic syndrome in older Chinese adults

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin